Compare WLDN & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WLDN | CERT |
|---|---|---|
| Founded | 1964 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Retail: Computer Software & Peripheral Equipment |
| Sector | Consumer Discretionary | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 978.7M |
| IPO Year | 2006 | 2020 |
| Metric | WLDN | CERT |
|---|---|---|
| Price | $80.19 | $6.12 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $123.25 | $12.22 |
| AVG Volume (30 Days) | 335.2K | ★ 3.7M |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 120.89 | 87.50 |
| EPS | ★ 3.49 | N/A |
| Revenue | $273,352,000.00 | ★ $418,838,000.00 |
| Revenue This Year | N/A | $4.26 |
| Revenue Next Year | $12.05 | $5.40 |
| P/E Ratio | $23.77 | ★ N/A |
| Revenue Growth | N/A | ★ 8.75 |
| 52 Week Low | $36.43 | $6.02 |
| 52 Week High | $137.00 | $15.38 |
| Indicator | WLDN | CERT |
|---|---|---|
| Relative Strength Index (RSI) | 36.82 | 32.74 |
| Support Level | $74.75 | $6.04 |
| Resistance Level | $119.59 | $7.52 |
| Average True Range (ATR) | 3.67 | 0.29 |
| MACD | 1.37 | -0.01 |
| Stochastic Oscillator | 60.42 | 9.55 |
Willdan Group Inc is a provider of professional technical and consulting services to utilities, private industry, and public agencies at all levels of government. It operates in the business segments of Energy and Engineering and Consulting. It generates the majority of its revenue from the Energy segment, which includes services such as audit and surveys, program design, master planning, benchmarking analysis, design engineering, construction management, performance contracting, installation, advances in software and data analytics, and other services. All of its revenue is derived from the domestic markets.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.